Daily News

Stakeholders clash on impact of IPR . . .

Rep. Issa Writing IPR Compromise Legislation

November 13, 2017
In the wake of the controversy surrounding Allergan’s decision to lease its patents for Restasis to a Native American tribe, the head of the congressional subcommittee with jurisdiction over the inter partes review process is writing legislation aimed at reforming the process. Rep. Darrell Issa (R-CA) said at a hearing Tuesday (Nov. 7) that he envisions the upcoming legislation as a compromise meant to address what some branded firms see as unfair advantages built into the IPR process for potential...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.